Completed PHASE1 INTERVENTIONAL 2-arm NCT00964106

Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation

An Open-label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Cytochrome P450 Probe Drugs in Healthy Adult Subjects

Sponsor: GlaxoSmithKline

Conditions Drug Interactions

Interventions Caffeine Dextromethorphan Fluconazole Flurbiprofen Ketoconazole Midazolam Omeprazole Rifampin Rosiglitazone Rosuvastatin

Updated 8 times since 2017 Last updated: Jan 2, 2018 Started: Aug 26, 2009 Primary completion: Aug 29, 2011 Completion: Aug 29, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00964106, this PHASE1 trial focuses on Drug Interactions and remains completed. Sponsored by GlaxoSmithKline, it has been updated 8 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jan 2018 — Jun 2018 [monthly]

Completed PHASE1
Jul 2017 — Jan 2018 [monthly]

Completed PHASE1
Jan 2017 — Jul 2017 [monthly]

Completed PHASE1

First recorded

Aug 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Busan, South Korea
• Seoul, South Korea